Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...

Denmark-based global pharma major, Novo Nordisk is now phasing out its Human Mixtard penfill by the year end. However Mixtard in India will continue to be available in vials. Along with it, other form ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part ...

The first 10 drugs targeted for negotiations were announced the following year — Novo’s rapid-acting insulin medication NovoLog among them — and new prices, agreed upon in 2024, are set to take effect ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

Rybelsus (semaglutide) is a prescription drug that’s used to manage blood sugar levels in people with type 2 diabetes. This drug can interact with other medications, such as levothyroxine ...

injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...